A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
BioNTech SE
BioNTech SE
University of Alabama at Birmingham
Evopoint Biosciences Inc.
Seagen Inc.
Theolytics Limited
Imunon
Immatics US, Inc.
National Institutes of Health Clinical Center (CC)
Bristol-Myers Squibb
Genmab
National Cancer Institute (NCI)
Imunon
Beijing Biotech
Parabilis Medicines, Inc.
National Institutes of Health Clinical Center (CC)
AstraZeneca
Eikon Therapeutics
Genmab
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
CanariaBio Inc.
Mayo Clinic
AstraZeneca
Alliance Foundation Trials, LLC.
Incyclix Bio
Compugen Ltd
858 Therapeutics, Inc.
Merck Sharp & Dohme LLC
Radiopharm Theranostics, Ltd
Blue Earth Diagnostics
Eisai Inc.
AstraZeneca
Terremoto Biosciences Inc.
GlaxoSmithKline
Taiho Oncology, Inc.
University of Louisville